The benefit of chemotherapy addition to endocrine therapy remains controversial in premenopausal patients. In this touchONCOLOGY interview Dr Oleg Gluz (West German Study Group, Mönchengladbach, Germany) discusses the ongoing phase III ADAPT cycle trial investigating the impact of age, recurrence score, and ovarian function suppression on endocrine therapy response.
The abstract entitled ‘Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials‘ Abstract LBA14, was presented at European Society for Medical Oncology (ESMO) 2022.
- What controversy persists around the addition of chemotherapy to endocrine therapy in premenopausal women with breast cancer? (0:26)
- Could you tell us a little about the ADAPT and ADAPTcycle clinical trials? (3:05)
- What were the aims and design of the current analysis? (5:09)
- What were the findings of the analysis? (7:50)
Disclosures: Oleg Gluz is on the advisory board for Roche, Lilly, Amgen, Novartis, Pierre Fabre, MSD, Celgene, Pfizer, Gilead, Molecular Health, Seagen; and has financial interests, and is an invited speaker for AstraZeneca, Exact Science, and Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Breast Cancer
Matthew Goetz, ESMO 2022: MONARCH 3 trial – Interim overall survival results of abemaciclib + NSAI in patients with HR+, HER2- advanced breast cancer
The MONARCH 3 trial led to abemaciclib plus nonsteroidal aromatase inhibitor approval as initial therapy in postmenopausal patients with hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer with significant improvement in progression-free survival. Prof. Matthew Goetz (Mayo Clinic, Rochester, MN, USA) joins touchONCOLOGY to discuss what the MONARCH 3 […]
Sara Tolaney, ESMO 2022: Clinical trial highlights in breast cancer
Dr Sara Tolaney joins touchONCOLOGY to discuss the latest clinical trial highlights in breast cancer, at ESMO 2022. She discusses the overall survival data from the TROPiCS-02 study, investigating sacituzumab govitecan-hziy versus treatment of physician’s choice in participants with HR+/HER2- metastatic breast cancer; and the overall survival data from the phase 3 MONARCH 3 trial, […]
Sara Tolaney, ESMO 2022: AMEERA-3 phase 2 study – Amcenestrant vs. endocrine treatment in patients with endocrine-resistant ER+/HER2− advanced breast cancer
Amcenestrant is an optimized oral selective ER degrader (SERD), which is being investigated in the AMEERA-3 (NCT04059484), an open-label phase II randomized study. In this touchONCOLOGY interview, Dr Sara Tolaney (Dana-Farber Cancer Institute, and Brigham and Women’s Hospital, Boston, MA, USA) discusses the phase II study, investigating amcenestrant versus endocrine treatment of physician’s choice in patients […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!